Menu Back toSession-2-Complex-Innovative-Designs

Biostatistics Industry and Regulator Forum

Session 2: Complex Innovative Designs

    Session Chair(s)
      Representative Invited

      Representative Invited

      • FDA, United States
      Amy  Xia, PhD

      Amy Xia, PhD

      • Executive Director, Biostatistics
      • Amgen, Inc., United States
    Both the 21st Century Cures Act and the PUDUFA VI legislations emphasize on complex innovative designs, which require simulations to understand the design operating characteristics, statistical properties, and operational features. This session will review and discuss the issues related to any complex trial design that we need to simulate the trial to understand its full behavior. Additionally, it will discuss analyses that are complex enough so that we likely need simulation for deeper understanding of the models. Examples of complex analyses include using hierarchical analyses and historical data will be given. A group of speakers and panelists will discuss opportunities and challenges relative to complex innovative designs and analyses in medical product development.

Contact us

Registration Questions?

Send Email

Call for Abstracts

Guidelines | Submit

Submission Deadline: February 12